Alembic Pharmaceuticals receives approval for Bupropion Hydrochloride Tablets

From USFDA

Alembic Pharmaceuticals has received USFDA approval for its Abbreviated New Drug Application (ANDA)Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Wellbutrin Tablets, 75 mg and 100 mg, of GlaxoSmithKline LLC. Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg is indicated for the treatment of major depressive disorder.

Powered by Capital Market - Live News